Renal transplant recipients receive immunosuppressive therapy to prevent acute rejection. We evaluated the immunopharmacological efficacy of vitamin K1 (VK1) and vitamin K2 (VK2) on T‐cell mitogen‐activated‐peripheral lymphocytes of dialysis patients… Click to show full abstract
Renal transplant recipients receive immunosuppressive therapy to prevent acute rejection. We evaluated the immunopharmacological efficacy of vitamin K1 (VK1) and vitamin K2 (VK2) on T‐cell mitogen‐activated‐peripheral lymphocytes of dialysis patients and healthy subjects.
               
Click one of the above tabs to view related content.